HIV Specialist - June 2021 - 25

care delivery is profound. While novel drug
delivery methods hold promise for further
improving the care of PWH, disruptive
financing models with a focus on equitable
care delivery could be more effective in
improving the long-term survival and reducing
the morbidity among those patients
living with HIV in Ethiopia and throughout
sub-Saharan Africa. HIV
DR. ANTENEH ZEWDE is an Internal
Medicine Hospitalist at the University of
Minnesota. He has a special interest in
implementation science and global
health in Ethiopia. Prior to starting
1. Orkin C, Arasteh K, Górgolas HernándezMora
M, et al. Long-Acting Cabotegravir
and Rilpivirine after Oral Induction for
HIV-1 Infection. N Engl J Med. 03
2020;382(12):1124-1135. doi:10.1056/
2. Swindells S, Andrade-Villanueva JF,
Richmond GJ, et al. Long-Acting
Cabotegravir and Rilpivirine for
Maintenance of HIV-1 Suppression. N
Engl J Med. 03 2020;382(12):1112-1123.
3. Orkin C, Oka S, Philibert P, et al.
Long-acting cabotegravir plus rilpivirine
for treatment in adults with HIV-1
infection: 96-week results of the
randomised, open-label, phase 3 FLAIR
study. Lancet HIV. 04
2021;8(4):e185-e196. doi:10.1016/
4. FDA Approves Cabenuva and Vocabria for
the Treatment of HIV Infection. https://
Landovitz RJ, Donnell D, Clement M,
Hanscom B. Pre-exposure Prophylaxis
containing long-acting injectable
cabotegravir is safe and highly effective
for cisgender men and transgender
women who have sex with men. AIDS July
6-10 2020.
6. Injectable Cabotegravir versus Oral
Truvada for Cisgender Women. November
16, 2020.
7. Monitoring selected national HIV
prevention and care objectives by using
HIV surveillance data-United States and
6 dependent areas, 2016.HIV Surveillance
Supplemental Report. Centers for Disease
Control and Prevention; 2018.
8. Sullivan PS, Satcher Johnson A,
Pembleton ES, et al. Epidemiology of HIV
in the USA: epidemic burden, inequities,
contexts, and responses. Lancet. Mar
2021;397(10279):1095-1106. doi:10.1016/
9. Lifson AR, Workneh S, Hailemichael A, et
al. Advanced HIV Disease among Males
and Females Initiating HIV Care in Rural
Ethiopia. J Int Assoc Provid AIDS Care.
2019 Jan-Dec 2019;18:2325958219847199.
10. Tesfaye B, Alebel A, Gebrie A, Zegeye A,
Tesema C, Kassie B. The twin epidemics:
Prevalence of TB/HIV co-infection and
its associated factors in Ethiopia; A
systematic review and meta-analysis.
PLoS One. 2018;13(10):e0203986.
11. Guidelines for Managing Advanced HIV
Disease and Rapid Initiation of
Antiretroviral Therapy. World Health
Organization; 2017.
12. Point-of-Care CD4 Tests To Support The
Identification of Individuals With
Advanced HIV Disease. World Health
Organization, HIV Treatment and Care
Team; April 3, 2020.
13. Guideline on when to start antiretroviral
therapy and on pre-exposure prophylaxis
for HIV. World Health Organization; 2015.
14. Beyene T, Zewde AG, Balcha A, et al.
Inadequacy of High-Dose Fluconazole
Monotherapy Among Cerebrospinal Fluid
Cryptococcal Antigen (CrAg)-Positive
Human Immunodeficiency VirusInfected
Persons in an Ethiopian CrAg
Screening Program. Clin Infect Dis. Nov
2017;65(12):2126-2129. doi:10.1093/cid/
15. Boulware DR, Meya DB, Muzoora C, et al.
Timing of antiretroviral therapy after
diagnosis of cryptococcal meningitis. N
Engl J Med. Jun 2014;370(26):2487-98.
16. Havlir DV, Kendall MA, Ive P, et al. Timing
of antiretroviral therapy for HIV-1
infection and tuberculosis. N Engl J Med.
Oct 2011;365(16):1482-91. doi:10.1056/
17. Hakim J, Musiime V, Szubert AJ, et al.
Enhanced Prophylaxis plus Antiretroviral
Therapy for Advanced HIV Infection in
Africa. N Engl J Med. 07 2017;377(3):233245.
18. Mfinanga S, Chanda D, Kivuyo SL, et al.
Cryptococcal meningitis screening and
community-based early adherence
support in people with advanced HIV
infection starting antiretroviral therapy in
Tanzania and Zambia: an open-label,
randomised controlled trial. Lancet. May
2015;385(9983):2173-82. doi:10.1016/
19. Updated recommendations on first-line
and second-line antiretroviral regimens
and post-exposure prophylaxis and
recommendations on early infant
diagnosis of HIV: interim guidelines.
Supplement to the 2016 consolidated
guidelines on the use of antiretroviral
drugs for treating and preventing HIV
infection.: Geneva: World Health
Organization; 2018.
20. Zash R, Holmes L, Diseko M, et al.
Neural-Tube Defects and Antiretroviral
Treatment Regimens in Botswana. N Engl
J Med. 08 2019;381(9):827-840.
21. Reepalu A, Arimide DA, Balcha TT, et al.
Drug Resistance in HIV-positive adults
during the initial year of antiretroviral
treatment at Ethiopian health centers.
Open Forum Infectious DiseasesMarch 6,
22. Kouanfack C, Mpoudi-Etame M, Omgba
Bassega P, et al. Dolutegravir-Based or
Low-Dose Efavirenz-Based Regimen for
the Treatment of HIV-1. N Engl J Med. 08
2019;381(9):816-826. doi:10.1056/
23. Venter WDF, Moorhouse M, Sokhela S, et
al. Dolutegravir plus Two Different
Prodrugs of Tenofovir to Treat HIV. N
Engl J Med. 08 2019;381(9):803-815.
24. Phillips AN, Bansi-Matharu L, Venter F, et
al. Updated assessment of risks and
benefits of dolutegravir versus efavirenz
in new antiretroviral treatment initiators
in sub-Saharan Africa: modelling to
inform treatment guidelines. Lancet HIV.
03 2020;7(3):e193-e200. doi:10.1016/
25. The United States President's Emergency
Plan for AIDS Relief. 2021 Annual Report
to Congress (2021).
26. Haile T, Hawulte B, Alemayehu S. A
Retrospective Cross-sectional Study on
the Prevalence and Factors Associated
with Virological Non-suppression among
HIV-Positive Adult Patients on
Antiretroviral Therapy in Woliso Town,
Oromia, Ethiopia. International Journal
of Medical and Health Sciences: World
Academy of Science, Engineering,
Technology; 2021.
27. Implementation Manual for Pre-Exposure
Prophylaxis (PreP) of HIV Infection. The
Federal Democratic Republic of Ethiopia,
Ministry of Health; 2019.
28. Updated recommendations on HIV
prevention, infant diagnosis, antiretroviral
initiation and monitoring: March 2021.:
Geneva: World Health Organization; 2021.
29. Mukherjee JS. An Introduction to Global
Health Delivery. Practice, Equity, Human
Rights. Oxford University Press; 2018.
30. Goyal R, Luca D, Klein PW, et al.
Cost-Effectiveness of HRSA's Ryan White
HIV/AIDS Program? J Acquir Immune
Defic Syndr. Feb 2021;86(2):174-181.
31. Adashi EY, Gruppuso PA. The Centers for
Medicare and Medicaid Services (CMS)
COVID-19 Brief: Unsettling Racial and
Ethnic Health Disparities. J Am Board
Fam Med. 02 2021;34(Suppl):S13-S15.
32. Lopez L, Hart LH, Katz MH. Racial and
Ethnic Health Disparities Related to
COVID-19. JAMA. 02 2021;325(8):719720.
33. Centers for Disease Control and
Prevention. HIV among African American
gay and bisexual men. 2018. Accessed
34. Centers for Disease Control and
Prevention. HIV among Hispanics/
residency at the University of Minnesota Dr. Zewde
worked in Ethiopia as a public health expert helping
push the national agenda for maternal health and
vaccines. In collaboration with the University of
Washington he worked to helped bridge the gap
between faith and medicine to help improve HIV
medication adherence. He spends three months
annually at hospitals affiliated with Arsi and Adama
University in Ethiopia and is engaged in ongoing
research, quality improvement, and implementation
internal medicine and pediatric
hospitalist at the University of Minnesota
and a credentialed member of the
American Academy of HIV Medicine.
Since 2019, he has also been working at a Ryan White
funded program in St Paul, Minnesota where is
provides primary care for PLWH. He has academic
interests in global health, point-of-care ultrasound,
and HIV prevention.
her degree in Clinical Infectious Disease
of Public Health Importance (CIDPH)
from the Mekelle University College of
Health Sciences. Since 2005, she has
been the HIV/AIDS prevention and treatment
Coordinator for the Adama Hospital and Medical
College. Within this role she overseas a broad range of
HIV treatment and prevention programs. She is also
involved with several ongoing research and quality
improvement projects.

HIV Specialist - June 2021

Table of Contents for the Digital Edition of HIV Specialist - June 2021

HIV Specialist - June 2021 - Cover1
HIV Specialist - June 2021 - Cover2
HIV Specialist - June 2021 - 1
HIV Specialist - June 2021 - 2
HIV Specialist - June 2021 - 3
HIV Specialist - June 2021 - 4
HIV Specialist - June 2021 - 5
HIV Specialist - June 2021 - 6
HIV Specialist - June 2021 - 7
HIV Specialist - June 2021 - 8
HIV Specialist - June 2021 - 9
HIV Specialist - June 2021 - 10
HIV Specialist - June 2021 - 11
HIV Specialist - June 2021 - 12
HIV Specialist - June 2021 - 13
HIV Specialist - June 2021 - 14
HIV Specialist - June 2021 - 15
HIV Specialist - June 2021 - 16
HIV Specialist - June 2021 - 17
HIV Specialist - June 2021 - 18
HIV Specialist - June 2021 - 19
HIV Specialist - June 2021 - 20
HIV Specialist - June 2021 - 21
HIV Specialist - June 2021 - 22
HIV Specialist - June 2021 - 23
HIV Specialist - June 2021 - 24
HIV Specialist - June 2021 - 25
HIV Specialist - June 2021 - 26
HIV Specialist - June 2021 - 27
HIV Specialist - June 2021 - 28
HIV Specialist - June 2021 - 29
HIV Specialist - June 2021 - 30
HIV Specialist - June 2021 - 31
HIV Specialist - June 2021 - 32
HIV Specialist - June 2021 - 33
HIV Specialist - June 2021 - 34
HIV Specialist - June 2021 - 35
HIV Specialist - June 2021 - 36
HIV Specialist - June 2021 - 37
HIV Specialist - June 2021 - 38
HIV Specialist - June 2021 - 39
HIV Specialist - June 2021 - 40
HIV Specialist - June 2021 - 41
HIV Specialist - June 2021 - 42
HIV Specialist - June 2021 - 43
HIV Specialist - June 2021 - 44
HIV Specialist - June 2021 - 45
HIV Specialist - June 2021 - 46
HIV Specialist - June 2021 - 47
HIV Specialist - June 2021 - 48
HIV Specialist - June 2021 - 49
HIV Specialist - June 2021 - 50
HIV Specialist - June 2021 - 51
HIV Specialist - June 2021 - 52
HIV Specialist - June 2021 - Cover3
HIV Specialist - June 2021 - Cover4